XZP-3621 + rifampicin

XZP-3621 is an orally administered, next-generation small molecule dual inhibitor targeting anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1). It is being developed primarily for the treatment of non-small cell lung cancer (NSCLC), especially in patients with ALK-positive or ROS1-positive tumors. The drug works by binding to and inhibiting the activity of ALK and ROS1 tyrosine kinases, thereby disrupting downstream signaling pathways that drive tumor growth in cancers expressing these targets[1][2][4]. XZP-3621 is under development by Xuanzhu Biopharmaceutical for use as a first-line therapy in advanced NSCLC, with ongoing clinical trials also exploring its efficacy in small cell lung cancer and lymphoma[2][4]. Rifampicin is not part of the investigational product but may be referenced due to potential drug-drug interaction studies; rifampicin is a strong CYP3A4 inducer that can affect the pharmacokinetics of many oral kinase inhibitors[6].